logo
Corrections: June 3, 2025

Corrections: June 3, 2025

New York Times03-06-2025
An article on May 25 about an unconventional program that claims to reverse Alzheimer's symptoms referred imprecisely to the sales of Dale Bredesen's book 'The End of Alzheimer's.' The title has sold around 300,000 copies in the United States, not overall.
Because of an editing error, an article on Sunday about a neighborhood on the outskirts of Berlin that was built for the elite guard of the Nazi Reich misidentified the spokesman for Vonovia, a company that serves as a landlord for some 300 apartments in the development was misidentified. He is Matthias Wulff, not Wulaaff.
An article on Sunday about the Energy Department's announcement that it was terminating $3.7 billion in Biden-era awards to companies trying to demonstrate technologies that might one day help tackle global warming misidentified the location of a Heidelberg Materials cement plant. It is in Indiana, not Louisiana.
An article on Saturday about a federal grand jury indicting a former New Hampshire businessman, Eric Spofford, on charges that he orchestrated attacks on the homes of journalists who had investigated claims of sexual misconduct against him misstated how much money Mr. Spofford is accused of paying an associate to vandalize the homes of a reporter and an editor at New Hampshire Public Radio as well as the home of the reporter's parents. It was $20,000, not $10,000.
An article on Sunday about the actress and singer Megan Hilty's routine on show days while she's starring in the Broadway musical 'Death Becomes Her' misstated Brian Gallagher's age. He is 45, not 52.
An obituary on May 23 about Jim Irsay, the owner and chief executive of the Indianapolis Colts of the National Football League, misstated the location of his death. It occurred in a hotel in Beverly Hills, Calif., not Los Angeles.
An obituary on Thursday about Bruce Logan, a special effects artist and cinematographer, using information from David Zucker, one of the directors of 'Airplane!,' misstated Mr. Logan's contribution to that film. He worked on miniatures; he did not design the title sequence.
Errors are corrected during the press run whenever possible, so some errors noted here may not have appeared in all editions.
To contact the newsroom regarding correction requests, please email nytnews@nytimes.com. To share feedback, please visit nytimes.com/readerfeedback.
Comments on opinion articles may be emailed to letters@nytimes.com.
For newspaper delivery questions: 1-800-NYTIMES (1-800-698-4637) or email customercare@nytimes.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pvolve Inks Four New Franchise Deals to Boost Expansion
Pvolve Inks Four New Franchise Deals to Boost Expansion

Yahoo

time11 minutes ago

  • Yahoo

Pvolve Inks Four New Franchise Deals to Boost Expansion

Functional Fitness Brand to Open Six Studios Across U.S. Markets Amid Rising Demand for Smarter Workouts NEW YORK, July 24, 2025 /PRNewswire/ -- Pvolve, the clinically-backed functional fitness franchise that strengthens, stabilizes, and mobilizes your body, continues to build on its national growth trajectory with the signing of four new franchise agreements. The latest expansion will introduce six studios across Highlands Ranch, Colorado; Atlanta North Perimeter, Georgia; Granger, Indiana; and Richmond, Virginia, further strengthening the brand's presence in key U.S. markets. Each new studio will be independently owned and operated by passionate entrepreneurs who are aligned with Pvolve's mission to deliver a smarter, more sustainable approach to fitness. The newly signed franchisees bring diverse professional backgrounds and a shared belief in the power of movement to transform lives: Highlands Ranch, Colo.: Adrianne Rodriguez, a former medical social worker with nearly 20 years of acute care experience, witnessed firsthand the profound impact of chronic illness and preventable conditions on individuals and families. She is bringing Pvolve to Highlands Ranch, eager to provide her community with a sustainable way to move, feel better and live longer, healthier lives. Atlanta North Perimeter, Ga.: Amber Jackson, with a background in marketing, publicity and corporate operations, expands her successful Pvolve presence with a second studio. As a driven entrepreneur and single mother, she's focused on building a business that supports her own balance while inspiring others to thrive, both physically and personally. Granger, Ind.: Lynn Haberland, vice president and COO of Michiana Neurologic Medicine, brings clinical operations expertise and a passion for wellness. Drawn to Pvolve's alignment with functional medicine, she aims to introduce a fitness method that supports sustainable health and movement. Richmond, Va.: Vikas Kapila, a seasoned franchise veteran and management consultant with experience owning consulting and StretchLab franchises, signed a three-unit agreement. Motivated by helping community members invest in themselves, Kapila was attracted to Pvolve's integrated approach to fitness and wellness. "As we grow, we're inspired by the caliber of franchise partners joining our system – leaders who bring strong business experience and are deeply connected to our brand's mission and values," said Julie Cartwright, President of Pvolve. "This next wave of growth reflects our commitment to meeting consumers where they are with a method that truly supports the body in motion through strength, stability and mobility." This expansion builds on Pvolve's most recent partnership with longevity-focused Tally Health, enhancing brand visibility, franchise development and member engagement, which are essential pillars for long-term success. Supported by a robust omnichannel model that integrates in-studio classes, digital streaming and proprietary equipment, Pvolve's franchise partners are uniquely positioned to serve today's wellness-focused consumers amid rising national demand. Franchise opportunities remain available in priority markets across the U.S., including Texas, Florida and North Carolina. Pvolve is actively seeking both single-unit and multi-unit operators who are mission-driven, community-focused and passionate about health and movement. To learn more about franchising with Pvolve, visit About PvolvePvolve is a workout method that redefines fitness with a method built on the principles of strength, mobility, and stability. As the first and only clinically-proven brand in the space, Pvolve continuously sets new standards for women's health in fitness, ensuring results you can see and feel for today and for the long haul. After being introduced to functional fitness in 2017, founder Rachel Katzman was determined to help others experience an approach that respects the body's holistic needs while making you look and feel great. The Pvolve Method is supported by a Clinical Advisory Board of doctors, as well as highly credentialed trainers, to offer effective workouts that help you break a sweat, not your body. In June 2023, world-renowned actress, producer, and director, Jennifer Aniston, officially partnered with Pvolve after falling in love with the method as a member, and referring to it as "transformational." Through its hybrid fitness model, Pvolve can be experienced through a streaming membership that offers over 1,500 on-demand classes, a two-way, live virtual studio, and targeted series, all available via the web and mobile apps. Additionally, Pvolve has 25 physical studio locations across the US and Canada, with more than 50 studios in development. For more information, please visit MEDIA CONTACT: Ashlyn Pinkowski, Fishman Public Relations, apinkowski@ View original content to download multimedia: SOURCE Pvolve

This British Comedian Auditioned For A Role In Barbie – But Lost Out To Will Ferrell
This British Comedian Auditioned For A Role In Barbie – But Lost Out To Will Ferrell

Yahoo

time11 minutes ago

  • Yahoo

This British Comedian Auditioned For A Role In Barbie – But Lost Out To Will Ferrell

Barbie was one of the most star-studded movies of the last decade, so it's no secret that competition was stiff to land a coveted role in such a stellar ensemble. Margot Robbie and Ryan Gosling starred in Greta Gerwig's Oscar-nominated movie about the iconic doll, completed by a cast that included Issa Rae, Kate McKinnon, Nicola Coughlan, Simu Liu, Ncuti Gatwa and many more. There was also a memorable supporting role from Will Ferrell, who played the rollerskating Mattel CEO. But before the gig went to the Anchorman actor, there was a British comedian up for the same role: James Acaster. The standup comic has been venturing into acting in recent years, having landed roles in Ghostbusters: Frozen Empire and last year's comedy-adventure film Seize Them! with The White Lotus star Aimee Lou Wood. View this post on Instagram A post shared by The Comedian's Comedian Podcast with Stuart Goldsmith (@comcompod) As revealed in a recently unearthed interview, the Off Menu podcast host also went for a role in the 2023 record-breaking blockbuster. Speaking on The Comedian's Comedian Podcast with Stuart Goldsmith last year, James opened up about his acting career when he was asked about projects he had unsuccessfully auditioned for. 'The Barbie movie. The part went to Will Ferrell,' James recalled, before adding: 'Come on, why are they even getting me in the room?' He also clarified that he 'liked the audition though', adding 'that's fun, it's learning'. Earlier this year, director Greta set the record straight following reports of a Barbie sequel. A spokesperson for the director insisted that there was 'no legitimacy' to the story that a follow-up was in the earlier stages, while Warner Bros. also called the reports 'inaccurate'. Meanwhile, Margot Robbie's film company is set to follow the success of Barbie by producing a new movie based on the Monopoly board game. Related... Type 1 Diabetes Barbie Has Taken The Internet By Storm – Here's Where To Buy Yours Barbie Director Greta Gerwig Sets The Record Straight After Fresh Sequel Reports From Minecraft To Barbie And Minions – Like It Or Not, Gen Alpha's TikTok Trends Are Shaping Cinema

Viking Therapeutics, Inc. (VKTX): A Bull Case Theory
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory

Yahoo

time11 minutes ago

  • Yahoo

Viking Therapeutics, Inc. (VKTX): A Bull Case Theory

We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, we will summarize the bulls' thesis on VKTX. Viking Therapeutics, Inc. 's share was trading at $32.07 as of July 17th. Viking Therapeutics (VKTX), a ~$3.45B biotech firm, is flying under the radar despite its potentially transformative role in the obesity treatment market. The investment thesis centers on VK2735, a GLP-1/GIP dual agonist for weight loss, being developed in both subcutaneous (Phase 3) and oral (Phase 2) forms—mirroring the mechanism of Eli Lilly's Mounjaro. The oral formulation's Phase 2 data is expected between late July and early September 2025, with projections pointing to best-in-class efficacy and safety. The obesity drug market, with estimates ranging from $95B to $158B by the early 2030s, presents a massive TAM. If VKTX captures even a modest share, its valuation could soar: base case implies $180/share on $5B in revenue, with a bull case of $360–540/share. The stock appears undervalued relative to its potential, trading at a steep discount despite having no debt, $852M in cash, and institutional ownership above 70%. A recent manufacturing agreement with CordenPharma secures scalable production capacity, de-risking the commercial path. Speculation of a buyout—possibly by Pfizer, which exited its own GLP-1 program—adds to the near-term catalysts. While bears raise concerns over market share and scale, the company has mitigated operational risks and may command premium terms in any M&A scenario. Despite its -48% decline over the past year, largely attributed to macro and short interest (~30%), VKTX offers an unusually asymmetric setup. With a potentially dominant pipeline and clear strategic optionality, VKTX stands as one of the most compelling high-risk/high-reward biotech investments today. Previously, we covered a on Viking Therapeutics, Inc. (VKTX) by Kontra Investments in February 2025, which highlighted the strong efficacy and superior safety of VK2735 in both subcutaneous and oral forms. The company's stock price has appreciated approximately by 13% since our coverage. Dritzz-9966 shares a similar view but emphasizes on near-term catalysts and asymmetric risk/reward potential. Viking Therapeutics, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 41 hedge fund portfolios held VKTX at the end of the first quarter which was 42 in the previous quarter. While we acknowledge the potential of VKTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store